ATE371193T1 - Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz - Google Patents

Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz

Info

Publication number
ATE371193T1
ATE371193T1 AT03796034T AT03796034T ATE371193T1 AT E371193 T1 ATE371193 T1 AT E371193T1 AT 03796034 T AT03796034 T AT 03796034T AT 03796034 T AT03796034 T AT 03796034T AT E371193 T1 ATE371193 T1 AT E371193T1
Authority
AT
Austria
Prior art keywords
screening
sedative
anxiolytic
potency
compounds
Prior art date
Application number
AT03796034T
Other languages
English (en)
Inventor
Jens Damsgaard Mikkelsen
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Application granted granted Critical
Publication of ATE371193T1 publication Critical patent/ATE371193T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9426—GABA, i.e. gamma-amino-butyrate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT03796034T 2002-11-28 2003-11-21 Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz ATE371193T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200201840 2002-11-28

Publications (1)

Publication Number Publication Date
ATE371193T1 true ATE371193T1 (de) 2007-09-15

Family

ID=32337947

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03796034T ATE371193T1 (de) 2002-11-28 2003-11-21 Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz

Country Status (7)

Country Link
US (1) US20060013770A1 (de)
EP (1) EP1567869B1 (de)
JP (1) JP4426461B2 (de)
AT (1) ATE371193T1 (de)
AU (1) AU2003298302A1 (de)
DE (1) DE60315876T2 (de)
WO (1) WO2004048980A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5183808B2 (ja) * 2008-08-29 2013-04-17 コンサート ファーマシューティカルズ インコーポレイテッド 置換トリアゾロ−ピリダジン誘導体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500828B1 (en) * 1999-01-27 2002-12-31 Merck Sharp & Dohme Ltd. Triazolo-pyridazine derivatives as ligands for gaba receptors
US7674463B1 (en) * 1999-07-15 2010-03-09 Research Development Foundation Method of inhibiting angiogenesis by administration of a corticotropin releasing factor receptor 2 agonist
AU780829B2 (en) * 1999-07-15 2005-04-21 Research Development Foundation Corticotropin releasing factor receptor 2 deficient mice and uses thereof

Also Published As

Publication number Publication date
WO2004048980A1 (en) 2004-06-10
EP1567869A1 (de) 2005-08-31
JP2006513405A (ja) 2006-04-20
US20060013770A1 (en) 2006-01-19
DE60315876T2 (de) 2008-05-21
EP1567869B1 (de) 2007-08-22
DE60315876D1 (de) 2007-10-04
AU2003298302A1 (en) 2004-06-18
JP4426461B2 (ja) 2010-03-03

Similar Documents

Publication Publication Date Title
ECSP055599A (es) AGONISMO DEL RECEPTOR DE 5HT2a PARA EL TRATAMIENTO DE DISFUNCION TERMORREGULADORA
PA8596901A1 (es) Inhibidores de p38 y metodos de uso de ellos
BRPI0415960A (pt) composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, composto ou um sal do mesmo, pró-droga de um composto, agente farmacêutico, inibidor de peptidase, uso de um composto,e, método para produzir um composto
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
BRPI0518563A2 (pt) moduladores de delta-opiàide tricÍclicos
EA200602221A1 (ru) Новое применение пептидных соединений для лечения боли при тригеминальной невралгии
UY28376A1 (es) Agentes terapéuticos
ATE497809T1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE441632T1 (de) Gesättigte und ungesättigte 3-pyridyl- benzocycloalkylmethyl-amine zur behandlung von schmerzen, depressionen und angstzuständen
NO20071604L (no) Loxapinanaloger og fremgangsmater for anvendelse derav.
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
MX2009003645A (es) Azaciclilaminas n-sustituidas como antagonistas de histamina-3.
DE602006008583D1 (de) Stabile kristalline form von bifeprunoxmesylat, dosierungsformen davon und verfahren zu deren verwendung
ATE481101T1 (de) Verfahren zur behandlung von angstzuständen
MX2009013205A (es) Derivados de pirazoloquinolina urea terapeuticos.
DE60220385D1 (de) Benzimidazole zur behandlung sexueller fehlfunktionen
HK1142775A1 (en) Therapeutic pyrazoloquinoline derivatives
ATE482211T1 (de) Imidazoä1,2-aüpyridin-anxiolytika
ATE494296T1 (de) Zusammensetzungen und verfahren für die tumordiagnose und behandlung
DE602006012313D1 (de) Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen
MX2009013197A (es) Derivados terapeuticos de pirazolonaftiridina.
ATE371193T1 (de) Verfahren zum screening für verbindungen mit sedativer oder anxiolytischer potenz
MXPA06000700A (es) Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
MXPA06000507A (es) Pirazolinas como antagonistas de par-1 para el tratamiento de enfermedades cardiovasculares.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties